MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SLS had $19,023K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$19,023K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-6,791 -12,414
Non-cash stock-based compensation
503 1,006
Non-cash lease expense
147 296
Prepaid expenses and other assets
635 1,423
Accounts payable
-1,031 -164
Accrued expenses and other current liabilities
897 -3,383
Operating lease liabilities
-158 -318
Net cash used in operating activities
-7,068 -16,400
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs
0 23,051
Proceeds from warrant inducement, net of issuance costs
22,027 -
Proceeds from the exercise of common stock warrants
4,000 4,712
Proceeds from employee stock purchases
64 48
Net cash provided by financing activities
26,091 27,811
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents
19,023 11,411
Cash and cash equivalents at beginning of period
13,986 -
Cash and cash equivalents at end of period
44,420 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc. (SLS)